Cover Image
Market Research Report
Product code 
1028953

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030

Published: Pre-Order | The Business Research Company | 175 Pages | Delivery time: 2-10 business days

Price

Back to Top
Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030
Published: Pre-Order
The Business Research Company
Content info: 175 Pages
Delivery time: 2-10 business days
  • ALL
  • Description
  • Table of Contents
Description

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2021: COVID-19 Growth And Change to 2030 from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global adalimumab, infliximab and etanercept biosimilars market.

This report focuses on adalimumab, infliximab and etanercept biosimilars market which is experiencing strong growth. The report gives a guide to the adalimumab, infliximab and etanercept biosimilars market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Where is the largest and fastest growing market for the adalimumab, infliximab and etanercept biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Adalimumab, Infliximab and Etanercept Biosimilars market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider adalimumab, infliximab and etanercept biosimilars market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The adalimumab, infliximab and etanercept biosimilars market section of the report gives context. It compares the adalimumab, infliximab and etanercept biosimilars market with other segments of the adalimumab, infliximab and etanercept biosimilars market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, adalimumab, infliximab and etanercept biosimilars indicators comparison.

Scope

Markets Covered:

1) By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others); Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola); Cipleumab (Erelzi, Eticovo)

2) By Application: Crohn'S Disease; Psoriatic Arthritis; Rheumatoid Arthritis; Ulcerative Colitis; Ankylosing Spondylitis; Plaque Psoriasis; Others

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Companies Mentioned: Zydus Cadila; Sandoz (Novartis); Samsung Bioepis; Abbvie; Amgen

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents
Product Code: h978

Table of Contents

1. Executive Summary

2. Adalimumab, Infliximab and Etanercept Biosimilars Market Characteristics

3. Adalimumab, Infliximab and Etanercept Biosimilars Market Trends And Strategies

4. Impact Of COVID-19 On Adalimumab, Infliximab and Etanercept Biosimilars

5. Adalimumab, Infliximab and Etanercept Biosimilars Market Size And Growth

  • 5.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Historic Market, 2015-2020, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Forecast Market, 2020-2025F, 2030F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation

  • 6.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Adalimumab biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, others)
  • Infliximab biosimilars (Inflectra, Renflexis, Ixifi, Avsola)
  • Cipleumab (Erelzi, Eticovo)
  • 6.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Crohn's disease
  • Psoriatic arthritis
  • Rheumatoid arthritis
  • Ulcerative colitis
  • Ankylosing spondylitis
  • Plaque psoriasis
  • Others
  • 6.3. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Adalimumab, Infliximab and Etanercept Biosimilars Market Regional And Country Analysis

  • 7.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • 7.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

8. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 8.1. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

9. China Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 9.1. China Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 9.2. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

10. India Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 10.1. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

11. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 11.1. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

12. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 12.1. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

13. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 13.1. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

14. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 14.1. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

15. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 15.1. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 15.2. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

16. UK Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 16.1. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

17. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 17.1. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

18. France Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 18.3. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

19. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 19.1. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 19.2. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

20. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 20.1. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

21. North America Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 21.1. North America Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 21.2. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

22. USA Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 22.1. USA Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 22.2. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

23. South America Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 23.1. South America Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 23.2. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

24. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 24.1. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

25. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 25.1. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 25.2. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

26. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market

  • 26.1. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
  • 26.2. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

27. Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Landscape And Company Profiles

  • 27.1. Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Landscape
  • 27.2. Adalimumab, Infliximab and Etanercept Biosimilars Market Company Profiles
    • 27.2.1. Zydus Cadila
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Sandoz (Novartis)
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Samsung Bioepis
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Abbvie
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Amgen
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Adalimumab, Infliximab and Etanercept Biosimilars Pipeline Analysis

29. Key Mergers And Acquisitions In The Adalimumab, Infliximab and Etanercept Biosimilars Market

30. Adalimumab, Infliximab and Etanercept Biosimilars Market Future Outlook and Potential Analysis

31. Appendix

  • 31.1. Abbreviations
  • 31.2. Currencies
  • 31.3. Research Inquiries
  • 31.4. The Business Research Company
  • 31.5. Copyright And Disclaimer